Adaptive Biotechnologies Corp. ADPT

Adaptive Biotechnologies has seen its share price move sharply in recent years, and the question now is whether the cash flows the business can generate really back up that kind of ride. With the stock recently closing at US$29.57 and investor attention drawn to new clinical guideline support for its testing platform, the focus turns to what the current valuation says about its future cash streams. Over the past 3 years the stock has returned about 432.8%, which puts a lot of weight on the...

Definition requires five years off myeloma treatment with sustained MRD negativity, assessed with technology sensitive enough to identify one myeloma cell among one million cellsSEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted the new consensus definition of cure for multi

Adaptive Biotechnologies (ADPT) is back in focus after the National Comprehensive Cancer Network updated multiple myeloma guidelines to more fully embed minimal residual disease testing and explicitly reference the company’s clonoSEQ assay. Investors have reacted quickly to the guideline update, with Adaptive Biotechnologies’ share price up 6.02% over the past day and posting a 12.65% 30-day share price return, while the 1-year total shareholder return of 125.21% and 3-year total shareholder...

Adaptive Biotechnologies recently highlighted updates to the National Comprehensive Cancer Network multiple myeloma guidelines, which now feature a dedicated page on minimal residual disease testing and specifically reference its FDA-cleared clonoSEQ assay with preferred high-sensitivity thresholds and expanded testing timepoints. The inclusion of clonoSEQ by name, alongside broader recommendations for routine and longitudinal MRD assessment, strengthens its position as a standardized tool...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) highlighted updated National Comprehensive Cancer Network, or NCCN, multiple myeloma guidelines on September 17. According to the announcement, the recommendations specifically name clonoSEQ and expand testing time points to include annual assessments during maintenance and testing after later treatment lines. The update strengthens the case for monitoring minimal residual disease, or […]

Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10-6 sensitivity now preferred SEATTLE, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted signifi

SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Tuesday, September 15, 20

While traders pointed to external clinical-trial momentum as a major catalyst, Tempus's own recent guidance raise and narrowing losses provided the underlying backdrop.

Adaptive Biotechnologies (ADPT) has surged 100% over the past year, driven by strong technical momentum. Shares recently hit a new 3-year high. Analyst sentiment is mixed with price targets ranging from $17 to $30. Investor focus has shifted from ADPT’s technology to its business execution, with technical indicators and momentum...

Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Adaptive Biotechnologies Corp (ADPT) reports a strong Q2 with MRD revenue up 49% (ex-milestones) and raises full-year guidance, while progressing the separation of its Immune Medicine business.

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +23.08% and +7.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

SEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2026. “We delivered an exceptional second quarter, driven by expanding growth and profitability in MRD, including both our clinical and biopharma busi